ஆர்ஸீநீ சிறப்பு மருந்தகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஆர்ஸீநீ சிறப்பு மருந்தகம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஆர்ஸீநீ சிறப்பு மருந்தகம் Today - Breaking & Trending Today

Orsini Specialty Pharmacy Selected By Sarepta Therapeutics As A Limited Distribution Partner For AMONDYS 45 (casimersen)


Orsini Specialty Pharmacy Selected By Sarepta Therapeutics As A Limited Distribution Partner For AMONDYS 45 (casimersen)
News provided by
Share this article
Share this article
ELK GROVE VILLAGE, Ill., March 4, 2021 /PRNewswire/ Orsini Specialty Pharmacy, the leading independent specialty pharmacy focused on rare diseases and gene therapies, announced today that it has been selected by Sarepta Therapeutics, Inc. as a limited distribution partner for AMONDYS 45 (casimersen). AMONDYS 45 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have genetic mutations on exon 45 of the dystrophin gene. For more information about AMONDYS 45, please see the Full Prescribing Information.  Orsini is the only specialty pharmacy with access to all approved DMD therapies. ....

Mike Fieri , Carla Sawa , Muscular Dystrophy Association , Care Team , Trademark Office , Sarepta Therapeutics Inc , Accreditation Commission For Health Care , Specialty Pharmacy , Sarepta Therapeutics , Full Prescribing , Parent Project Muscular , Orsini Chief Executive , Elk Grove Village , Orsini Specialty Pharmacy , Accreditation Commission , Health Care , Joint Commission , Rare Diseases , Prescribing Information , Full Prescribing Information , மைக் பீேரி , கார்லா சாவா , தசை டிஸ்ட்ரோபி சங்கம் , பராமரிப்பு அணி , முத்திரை அலுவலகம் , சாறெப்டா சிகிச்சை இன்க் ,

Orsini Specialty Pharmacy Selected By Glaukos® Corporation As A Specialty Pharmacy Distribution Partner For Photrexa® And Photrexa® Viscous


Orsini Specialty Pharmacy Selected By Glaukos® Corporation As A Specialty Pharmacy Distribution Partner For Photrexa® And Photrexa® Viscous
News provided by
Share this article
Share this article
ELK GROVE VILLAGE, Ill., Jan. 19, 2021 /PRNewswire/  Orsini Specialty Pharmacy, a leader in rare diseases and gene therapies, announced today that it has been selected by Glaukos
® Corporation as a specialty pharmacy distribution partner for Photrexa
® (riboflavin 5 -phosphate ophthalmic solution) and Photrexa
® Viscous (riboflavin 5 -phosphate in 20% dextran ophthalmic solution) for the treatment of patients with progressive keratoconus and corneal ectasia following refractive surgery See Full Prescribing Information. Using Photrexa Viscous and Photrexa with a proprietary UV light delivery system, Glaukos iLink™ corneal cross-linking procedure is the first and only FDA approved therapeutic treatment that strengthens the cornea to slow or halt the p ....

United States , Mike Fieri , Glaukos Corporation , Photrexa Care Team , Accreditation Commission For Health Care , Orsini Specialty Pharmacy , Full Prescribing , Using Photrexa Viscous , Orsini Chief Executive , Global Market Access , Elk Grove Village , Accreditation Commission , Health Care , Joint Commission , Rare Diseases , Micro Invasive Glaucoma Surgery , ஒன்றுபட்டது மாநிலங்களில் , மைக் பீேரி , அங்கீகாரம் தரகு க்கு ஆரோக்கியம் பராமரிப்பு , ஆர்ஸீநீ சிறப்பு மருந்தகம் , முழு ப்ரிஸ்க்ரைபிஂக் , ஆர்ஸீநீ தலைமை நிர்வாகி , உலகளாவிய சந்தை நுழைவு , அங்கீகாரம் தரகு , ஆரோக்கியம் பராமரிப்பு , கூட்டு தரகு ,